Brief: Repare Therapeutics & Debiopharm Announce First Patient Dosed In Phase 1/1B Mythic Trial
30/04/2024 12:07
April 30 (Reuters) - Repare Therapeutics Inc RPTX.O :
* REPARE THERAPEUTICS & DEBIOPHARM ANNOUNCE FIRST PATIENT
DOSED IN
PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL
COMBINATION OF PKMYT1 AND WEE1 INHIBITION
Source text for Eikon: ID:nBw4vd4Sza
Further company coverage: RPTX.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Repare Therapeutics
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Repare Therapeutics Announces Acquisition Of Polθ ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
Brief: Repare Signs Support Agreements With Key Shareholders For Xenotherapeutics Deal
Repare Therapeutics Q2 net loss narrows to $16.7 mln